Targeting mitochondria in pulmonary hypertension

October 25, 2017, University of Alberta Faculty of Medicine & Dentistry
A new compound called DCA improved lung function for pulmonary arterial hypertension patients. Credit: E.D. Michelakis et al., Science Translational Medicine (2017)

Pulmonary Arterial Hypertension (PAH) is a debilitating disease of the lung blood vessels that causes heart failure and early death, affecting hundreds of thousands of patients worldwide. Available therapies fail to prolong life, despite costs that may exceed $200,000/patient per year. A team of investigators at the University of Alberta (Edmonton, Canada), and the Imperial College of Medicine (London, UK), reported promising results of an early-phase clinical trial with a novel drug in PAH patients, already under treatment with approved drugs.

In this week's issue of Science Translational Medicine, the investigators showed that the generic drug, Dichloroacetate (DCA), can decrease the blood pressure in the lungs of PAH patients and improve their ability to walk, without significant side effects at the doses tested.

DCA works by activating mitochondria, the energy-producing units of the cell, which also regulate the cell's fate (i.e., whether the cell can grow or die by self-destruction), a process called apoptosis. Mitochondrial function is suppressed in PAH. This allows the cells lining the lumen of vessels to grow and avoid apoptosis. The resulting overgrowth of cells narrows the lumen of vessel, making the heart work harder to push blood through for oxygenation. This overgrowth of cells resembles the growth of cancer cells, where is also suppressed and DCA has shown promise as a potential cancer treatment.

The investigators also studied lungs from PAH patients removed at transplant surgery. They were able to keep them alive for a few hours by connecting them to a respirator and perfusing them with nutrients, with or without DCA. They showed that the molecular target of DCA (a mitochondrial enzyme called Pyruvate Dehydrogenase Kinase or PDK) was higher in the lungs of PAH patients compared to lungs that do not have the disease, and that DCA effectively inhibits the enzyme, increasing mitochondrial function. In addition to measuring the pressures on the patient lungs in the clinical trial, the investigators used and computed tomography (PET-CT) and showed that the patients' lung metabolism improved, due to increased mitochondrial lungs, much like in the explanted lungs. "This is the first time that a drug targeting mitochondria is shown to be effective in patients with PAH" said Dr. Evangelos Michelakis, the study's co-lead.

Targeting mitochondria in pulmonary hypertension
Ex vivo lung from a patient with pulmonary arterial hypertension who went on to receive a transplant. Credit: E.D. Michelakis et al., Science Translational Medicine (2017)

While no patient worsened, some patients (and some lungs) simply did not respond to DCA. The investigators showed that in these patients, the presence of two gene variants (single nucleotide polymorphisms) encoding two mitochondrial proteins were causing a mitochondrial suppression that was unrelated to PDK and thus not responsive to DCA. "This is a great example of precision medicine, where the patients' genes can be used to predict the effectiveness of a drug in a particular patient," said Dr. Martin Wilkins, the study's co-lead. "This work will be important for the design of future trials with DCA (or other mitochondrial activators). We would spare patients carrying these two gene variants from recruitment to a study from which they may not benefit, allowing them to enroll in other studies. By focusing on that have a greater chance of improvement, we can increase the efficiency and decrease the cost of trials," said Wilkins.

"Another important aspect of the study is that DCA is a , and thus the study was not sponsored by a pharmaceutical company, but from public funds and donations. This means that if future studies confirm our results and show a clear and definitive benefit of DCA in PAH, we may have an affordable, cheap treatment available to all," said Michelakis.

Movie of a lung that was removed from a patient with PAH who underwent transplant surgery, showing a set up for studying the effects of new potential treatments. Credit: Drs Michelakis, Nagendran and Freed, University of Alberta, Edmonton, Canada

Explore further: New clinical care guidelines issued for patients with mitochondrial disease

More information: E.D. Michelakis el al., "Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients," Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/ … scitranslmed.aao4583

Related Stories

New clinical care guidelines issued for patients with mitochondrial disease

October 25, 2017
Physicians who see patients with mitochondrial disease now have a practical new tool—a set of guidelines for managing and caring for those patients. Occurring in at least one in 4,500 individuals, mitochondrial disease ...

New genetic test for predicting cancer recurrence

September 21, 2017
Researchers have discovered a new genetic test which could help predict cancer recurrence - paving the way for more precise, personalised treatments.

Stem cells could offer hope for patients with lung damage from COPD and asthma

September 27, 2017
Early stage trials have shown promise for a cell-based therapy for treating lung tissue damaged by respiratory diseases.

Unlocking the secrets of pulmonary hypertension

October 30, 2014
A UAlberta team has discovered that a protein that plays a critical role in metabolism, the process by which the cell generates energy from foods, is important for the development of pulmonary hypertension, a deadly disease.

Neurodegenerative disease mechanism and potential drug identified

June 6, 2017
Two new studies of progressive, neurodegenerative diseases linked to defects in cells' mitochondria offer hope for developing a new biomarker for research and diagnostics, and a drug for treating such diseases, report researchers ...

Recommended for you

New compound shown to be as effective as FDA-approved drugs against life-threatening infections

June 15, 2018
Purdue University researchers have identified  a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections ...

Foods combining fats and carbohydrates more rewarding than foods with just fats or carbs

June 14, 2018
Researchers show that the reward center of the brain values foods high in both fat and carbohydrates—i.e., many processed foods—more than foods containing only fat or only carbs. A study of 206 adults, to appear June ...

3-D imaging and computer modeling capture breast duct development

June 14, 2018
Working with hundreds of time-lapse videos of mouse tissue, a team of biologists joined up with civil engineers to create what is believed to be the first 3-D computer model to show precisely how the tiny tubes that funnel ...

Beating cancer at its own game with a Trojan horse telomerase

June 13, 2018
Telomerase is a reverse transcriptase that uses an RNA template to synthesize telomeres. These repeat sequences bind special proteins that fold the ends of chromosomes back onto themselves to create a stable cap. When this ...

Turning the tables on the cholera pathogen

June 13, 2018
Recent cholera outbreaks in regions that are ravaged by war, struck by natural disasters, or simply lack basic sanitation, such as Yemen or Haiti, are making the development of new and more effective interventions a near-term ...

Troves from a search for new biomarkers: blood-borne RNA

June 12, 2018
It's the critical first step in treating everything from strokes to cancer: a timely and accurate diagnosis. Today, doctors often rely on biomarkers, such as cardiac troponin, the protein that appears in the blood after a ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.